Comprehensive genomic profiling of advanced esophageal squamous cell carcinomas and esophageal adenocarcinomas reveals similarities and differences

Oncologist

Volumn 20, Issue 10, 2015, Pages 1132-1139

  Wang, Kai ^a   Johnson, Adrienne ^a   Ali, Siraj M ^a   Klempner, Samuel J ^b   Bekaii Saab, Tanios ^c   Vacirca, Jeffrey L ^d   Khaira, Depinder ^a   Yelensky, Roman ^a   Chmielecki, Juliann ^a   Elvin, Julia A ^a   Lipson, Doron ^a   Miller, Vincent A ^a   Stephens, Philip J ^a   Ross, Jeffrey S ^a,e  

^a FOUNDATION MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d National Translational Research Group   (United States)

^e ALBANY MEDICAL COLLEGE   (United States)

Author keywords

Adenocarcinoma; Comprehensive genomic profiling; Esophageal cancer; Next generation sequencing; Squamous cell; Targeted therapy

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 9; K RAS PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MIXED LINEAGE LEUKEMIA PROTEIN; NOTCH1 RECEPTOR; NUCLEAR FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA BINDING PROTEIN 1; SMAD4 PROTEIN; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; TRANSCRIPTOME;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE AMPLIFICATION; GENE DOSAGE; GENE FREQUENCY; GENE SEQUENCE; GENETIC PROCEDURES; GENOMIC PROFILING; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; INTRON; MAJOR CLINICAL STUDY; MALE; NEXT GENERATION SEQUENCING; POINT MUTATION; PRIORITY JOURNAL; ADENOCARCINOMA; ESOPHAGUS TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; SQUAMOUS CELL CARCINOMA; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; TRANSCRIPTOME;

EID: 84943237946     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2015-0156     Document Type: Article

References (42)

1. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med 2003;349:2241-2252.
2. Engel LS, Chow WH, Vaughan TL et al. Population attributable risks of esophageal and gastric cancers. JNatl Cancer Inst 2003;95:1404- 1413.
3. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 2013;63:232-248.
4. Pennathur A, Gibson MK, Jobe BA et al. Oesophageal carcinoma. Lancet 2013;381:400- 412.
5. Al-Haddad S, El-Zimaity H, Hafezi-Bakhtiari S et al. Infection and esophageal cancer. Ann N Y Acad Sci 2014;1325:187-196.
6. Michaelsen SH, Larsen CG, von Buchwald C. Human papillomavirus shows highly variable prevalence in esophageal squamous cell carcinoma and no significant correlation to p16INK4a overexpression: A systematic review. J Thorac Oncol 2014;9: 865-871.
7. Hardefeldt HA, Cox MR, Eslick GD. Association between human papillomavirus (HPV) and oesophageal squamous cell carcinoma: Ameta-analysis. Epidemiol Infect 2014;142:1119-1137.
8. Tepper J, Krasna MJ, Niedzwiecki D et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol 2008;26:1086- 1092.
9. Walsh TN, Noonan N, Hollywood D et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 1996; 335:462-467.
10. Cunningham D, Allum WH, Stenning SP et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20.
11. SjoquistKM, Burmeister BH, SmithersBMet al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: An updated meta-analysis. Lancet Oncol 2011;12:681-692.
12. Jang R, Darling G, Wong RK. Multimodality approaches for the curative treatment of esophageal cancer. J Natl Compr Canc Netw 2015;13:229- 238.
13. Little AG, Lerut AE, Harpole DH et al. The Society of Thoracic Surgeons practice guidelines on the role of multimodality treatment forcancer of the esophagus and gastroesophageal junction. Ann Thorac Surg 2014;98:1880-1885.
14. Paul S, Altorki N. Outcomes in the management of esophageal cancer. J Surg Oncol 2014;110: 599-610.
15. Kleinberg L, Forastiere AA. Chemoradiation in the management of esophageal cancer. J Clin Oncol 2007;25:4110-4117.
16. Duan XF, Tang P, Yu ZT. Neoadjuvant chemoradiotherapy for resectable esophageal cancer: An in-depth study of randomized controlled trials and literature review. Cancer Biol Med 2014;11:191- 201.
17. Lloyd S, Chang BW. Current strategies in chemoradiation for esophageal cancer. J Gastrointest Oncol 2014;5:156-165.
18. Bang YJ, Van Cutsem E, Feyereislova A et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2- positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet 2010;376: 687-697.
19. Almhanna K, Meredith KL, Hoffe SE et al. Targeting the human epidermal growth factor receptor 2 in esophageal cancer. Cancer Contr 2013;20:111-116.
20. Forde PM, Kelly RJ. Genomic alterations in advanced esophageal cancer may lead to subtypespecific therapies. The Oncologist 2013;18:823- 832.
21. Belkhiri A, El-Rifai W. Advances in targeted therapies and new promising targets in esophageal cancer. Oncotarget 2015;6:1348-1358.
22. Agrawal N, Jiao Y, Bettegowda C et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Cancer Discov 2012;2:899-905.
23. StreppelMM,Lata S, DelaBastideMet al. Nextgeneration sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus. Oncogene 2014;33:347-357.
24. Dulak AM, Schumacher SE, van Lieshout J et al. Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis. Cancer Res 2012;72:4383-4393.
25. Frampton GM, Fichtenholtz A, Otto GA et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol 2013;31: 1023-1031.
26. Forbes SA, Bindal N, Bamford S et al. COSMIC: Mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-D950.
27. Compeau PE, Pevzner PA, Tesler G. How to apply de Bruijn graphs to genome assembly. Nat Biotechnol 2011;29:987-991.
28. Dulak AM, Stojanov P, Peng S et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifies recurrent driver events and mutational complexity. Nat Genet 2013;45: 478-486.
29. Song Y, Li L,OuY et al. Identification ofgenomic alterations in oesophageal squamous cell cancer. Nature 2014;509:91-95.
30. Lin DC, Hao JJ, Nagata Y et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014;46:467-473.
31. Gao YB, Chen ZL, Li JG et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 2014;46:1097-1102.
32. Bandla S, Pennathur A, Luketich JD et al. Comparative genomics of esophageal adenocarcinoma and squamous cell carcinoma. Ann Thorac Surg 2012;93: 1101-1106.
33. Sagatys E, Garrett CR, Boulware D et al. Activation of the serine/threonine protein kinase Akt during the progression of Barrett neoplasia. Hum Pathol 2007;38:1526-1531.
34. Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol 2010;28:1075-1083.
35. Hanawa M, Suzuki S, Dobashi Y et al. EGFR protein overexpression and gene amplification in squamous cell carcinomas of the esophagus. Int J Cancer 2006;118:1173-1180.
36. Kato H, Arao T, Matsumoto K et al. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol 2013;42:1151-1158.
37. Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: Past experiences and challenges. Neuro-oncol 2014;16(suppl 8):viii7- viii13.
38. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): A randomised, openlabel phase 3 trial. Lancet Oncol 2013;14:490- 499.
39. Waddell T, Chau I, Cunningham D et al. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): A randomised, open-label phase 3 trial [published correction appears in Lancet Oncol 2013;14:e254]. Lancet Oncol 2013;14:481-489.
40. Sugiura K, Ozawa S, Kitagawa Y et al. Coexpression of aFGF and FGFR-1 is predictive of a poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep 2007;17:557- 564.
41. Dienstmann R, Rodon J, Prat A et al. Genomic aberrations in the FGFR pathway: Opportunities for targeted therapies in solid tumors. Ann Oncol 2014;25:552-563.
42. Kwak EL, LoRusso P, Hamid O et al. Clinical activity of AMG 337, an oral MET kinase inhibitor, in adult patients with MET-amplified gastroesophageal junction, gastric, or esophageal cancer. J Clin Oncol 2015;33(suppl 3):1a.